(1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases

US9540379B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Hans-Joachim Lankau · Weinböhla, DE
• Barbara Langen · Radebeul, DE
• Christian Grunwald · Dresden, DE
• Norbert Hoefgen · Radeberg, DE
• Hans Stange · Riesa, DE
• Rita Dost · Dresden, DE
• Ure Egerland · Radebeul, DE

Key dates

• Filing date: Jan 30, 2012
• Grant date: Jan 10, 2017
• Expiry date: Jul 29, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.